Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction

Journal of Cellular Physiology

Volumn 228, Issue 10, 2013, Pages 2063-2070

  Babick, Andrea ^a   Elimban, Vijayan ^a   Zieroth, Shelley ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BETA ADRENERGIC RECEPTOR; CALCIUM ION; DOPAMINE; MESSENGER RNA; METOPROLOL; MYOSIN HEAVY CHAIN ALPHA; NORADRENALIN; PHOSPHOLAMBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART OUTPUT; HEART VENTRICLE WALL; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIAC OUTPUT; DOPAMINE; EPINEPHRINE; HEART; HEART FAILURE; HEART RATE; HEART VENTRICLES; MALE; METOPROLOL; MYOCARDIAL INFARCTION; MYOSIN HEAVY CHAINS; NOREPINEPHRINE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA, MESSENGER; SARCOPLASMIC RETICULUM; VENTRICULAR REMODELING;

ANIMALIA; RATTUS;

EID: 84879580673     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24373     Document Type: Article

References (52)

1. Adameova A, Abdellatif Y, Dhalla NS. 2009. Role of the excessive amounts of circulation catrecholamines and glucocorticoids in stress-induced heart disease. Can J Phys Pharm 87:493-514.
2. Ahmet I, Morrell C, Lakatta EG, Talan MI. 2009. Therapeutic efficacy of a combination of a beta1-adrenoceptor(AR) blocker and beta2-AR agonist in a rat model of post-myocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 331:178-185.
3. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. 2001. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104:2194-2199.
4. Babick A, Chapman D, Zieroth S, Elimban V, Dhalla NS. 2012a. Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. J Cell Mol Med 16:2958-2967.
5. Babick A, Elimban V, Dhalla NS. 2012b. Reversal of cardiac remodelling and subcellular defects by prazosin in heart failure due to myocardial infarction. J Clin Exp Cardiolog S5:009. DOI: 10.4172/2155-9880, S5-009
6. Briest W, Holzl A, Rabler B, Deten A, Baba HA, Zimmer H. 2003. Significance of matrix metalloproteinases in norepinephrine-induced remodeling of rat hearts. Cardiovasc Res 57:379-387.
7. Brophy JM, Joseph L, Rouleau JL. 2001. Beta-blockers in congestive heart failure A Bayesian meta-analysis. Ann Intern Med 134:550-560.
8. Chang HY, Klein RM, Kunos G. 1982. Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats. J Pharmacol Exp Ther 221:784-789.
9. Cohn JN, Ferrari R, Sharpe N. 2000. Cardiac remodeling-Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35:569-582.
10. Cohn JN, Levine TB, Olivari MET, Garberg V, Lura D, Francis GS. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823.
11. Dargie HJ. 2001. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385-1390.
12. th World Congress on Heart Disease. Medimond International Proceedings, Bologna, 81- 85.
13. Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. 2006. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Therapeut 11:31-45.
14. Dhalla NS, Rangi S, Babick AP, Zieroth S, Elimban V. 2012. Cardiac remodeling and subcellular defects in heart failure due to myocardial infarction and aging. Heart Fail Rev; DOI: 10.1007/s10741-011-9278-7
15. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS. 2009. Subcelluilar remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 81:429-438.
16. Dixon IM, Lee SL, Dhalla NS. 1990. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res 66:782-788.
17. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. 2003. Sympathetic nerve activity and neurotransmitter release in humans: Translation from pathophysiology into clinical practice. Acta Physiol Scand 177:275-284.
18. Fedak PWM, Verma S, Weisel RD, Li R. 2005. Cardiac remodeling and failure from molecules to man (Part I). Cardiovasc Physiol 12:1-11.
19. George I, Sabbah HN, Xu K, Wang N, Wang J. 2011. β-adrenergic receptor blockade reduces endoplasmic reticulum stress and normalizes calcium handling in coronary embolization model of heart failure in canines. Cardiovasc Res 91:447-455.
20. Guo X, Chapman D, Dhalla NS. 2003. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol Cell Biochem 254:163-172.
21. Krum H. Beta-blockers in heart failure. 1999. The 'new wave' of clinical trials. Drugs 58:203-210.
22. Latini R, Masson S, Jeremic G, Luvarà G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S. 1998. Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 31:601-608.
23. ++-ATPase in mammalian ventricle. J Pharmacol Exp Ther 286:531-538.
24. Machackova J, Barta J, Dhalla NS. 2006. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol 22:953-968.
25. Machackova J, Sanganalmath SK, Barta J, Dhalla KS, Dhalla NS. 2010. Amelioration of cardiac remodelling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol 10:9-16.
26. Machackova J, Sanganalmath SK, Elimban V, Dhalla NS. 2011. β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 15:545-554.
27. 2+ handling in the post-infarction rat heart. Cardiovasc Res 79:42-51.
28. 2+/calmodulin dependent protein kinase is altered in heart failure. Circ Res 86:596-605.
29. 1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 94:353-358.
30. Ni L, Zhou C, Duan Q, Lv J, Fu X, Xia Y, Wang DW. 2011. β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One 6:e27294.
31. Omerovic E, Bollano E, Mobini R, Madhu B, Kujacic V, Soussi B, Hjalmarson A, Waagstein E. 2001. Selective beta(1)-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling. Biochem Biophys Res Commun 281:491-498.
32. Omerovic E, Bollano E, Soussi B, Waagstein F. 2003. Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur J Heart Fail 5:725-732.
33. Packer M, Coats AJ, Fowler MB., et al. 2001. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658.
34. Panagia V, Pierce GN, Dhalla KS, Ganguly PK, Beamish RE, Dhalla ??. 1985. Adaptive changes in subcellular calcium transport during catecholamine-induced cardiomyopathy. J Mol Cell Cardiol 17:411-420.
35. 2+-handling proteins and heart failure: novel molecular targets? Curr Med Chem 10:967-981.
36. Ren B, Shao Q, Ganguly PK, Tappia PS, Takeda N, Dhalla NS. 2004. Influence of long-term treatment of imidapril on mortality, cardiac function, and gene expression in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 82:1118-1127.
37. Rouleau JL. 1996. The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol 12:3F-8F.
38. Sabbah HN. 1999. The cellular and physiologic effects of beta-blockers in heart failure. Clinical Cardiol 22:V16-V20.
39. Saini HK, Shao Q, Musat S, Takeda N, Tappia PS, Dhalla NS. 2005. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol 144:202-211.
40. Sallach JA, Goldstein S. 2003. Use of beta-blockers in congestive heart failure. Ann Med 35:259-266.
41. Sanganalmath SK, Babick AP, Barta J, Kumamoto H, Takeda N, Dhalla NS. 2008a. Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure. J Cell Mol Med 12:1728-1738.
42. Sanganalmath SK, Barta J, Takeda N, Kumamoto H, Dhalla NS. 2008b. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 86:180-189.
43. 2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 288:H2637-2646.
44. 2+-transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol 288:H1674-H1682.
45. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. 2005. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128:1812-1821.
46. Temsah RM, Netticadan T, Chapman D, Takeda S, Mochizuki S, Dhalla NS. 1999. Alterations in sarcoplasmic reticulum function and gene expression in ischemia-reperfused rat heart. Am J Physiol 277:H584-H594.
47. Torres RA. 2009. Carotid body and sympathetic activation in heart failure: a story of sensors and sensitivity. Cardiovasc Res 81:633-634.
48. Wang J, Guo X, Dhalla NS. 2004. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta 1690:177-184.
49. Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS. 2002. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol 34:847-857.
50. White CM. 1998. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm 55:676-682.
51. i transients in hypertensive and postinfarction myoctyes. Am J Physiol Cell Physiol 269:C632-C640.
52. Zhang X-Q, Musch TI, Zelis R, Cheung JY. 1999. Effects of impaired Ca2+ homeostasis on contraction in postinfarction myocytes. J Appl Physiol 86:943-950.